Teva Pharma (TEVA) Tops Q2 EPS by 5c; Guides In-Line
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Mizuho Securities Cuts Price Target on Teva Pharma (TEVA) Following 2Q Beat
August 8, 2016 6:53 AM EDTMizuho Securities maintained a Buy rating on Teva Pharma (NYSE: TEVA), and cut the price target to $70.00 (from $75.00), following the company's 2Q earnings report. TEVA reported revenue of $5.0B and $1.25 EPS, vs. $4.88B and $1.20 consensus and management's recent guidance of $4.9- $5.0B and... More
Teva (TEVA): Soft 2Q Underscores Need For Actavis - Piper Jaffray
August 5, 2016 9:03 AM EDTPiper Jaffray analyst David Amsellem bumped his price target on Teva Pharma (NYSE: TEVA) to $57.00 (from $55.00) but maintained a Neutral rating following Q2 results.
Amsellem commented, "Teva reported 2Q16 non-GAAP diluted EPS of $1.25 on revenue of $5.04B; recall that the company pre-announced... More
Oppenheimer Downgrades Teva Pharma (TEVA) to Perform
August 5, 2016 7:27 AM EDTOppenheimer downgraded Teva Pharma (NYSE: TEVA) from Outperform to Perform and removed its price target (prior $72.00).
For an analyst ratings summary and ratings history on Teva Pharma click here. For more ratings news on Teva Pharma click here.
Shares of Teva Pharma closed at $55.45 yesterday.
... More